6-K

UNITED STATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM 6-K

REPORT OFFOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THESECURITIES EXCHANGE ACT OF 1934

For the month of October 2020

Commission File Number: 001-31995

MEDICUREINC.

(Translation of registrant's name into English)

2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.

EXHIBITLIST

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 99.1

Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar

WINNIPEG, AB, Oct. 5, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, announces that through its wholly-owned subsidiary, Medicure International Inc., it has entered into a License, Manufacture and Supply Agreement (the "Agreement") with Reliance Life Sciences Private Limited ("RLS") for a cardiovascular biosimilar (the "Product"). Medicure is responsible for the regulatory approval process for the Product. A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an approved reference product. The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.

"We are very pleased with the agreement we have reached with RLS. The Product fits well with Medicure's mission of being a significant cardiovascular company focused on the U.S. market." commented Dr. Albert Friesen, Chief Executive Officer for Medicure. "We look forward to the growth of our portfolio of cardiovascular products."

**About Medicure Inc.**Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT^®^ (tirofiban hydrochloride) injection and ZYPITAMAG^TM^ (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com. For additional information about ZYPITAMAG^TM^, refer to the full Prescribing Information.

About Reliance Life Sciences Private LimitedReliance Life Sciences Private Limited (RLS) is part of the Promoter Group of Reliance Industries Limited. RLS is a research driven organization developing business opportunities in bio-therapeutics (plasma proteins, biosimilars and novel proteins), pharmaceuticals, regenerative medicine, clinical research services, and molecular medicine. The Reliance Group is India's largest private sector enterprise, with annual revenues of $ 86 billion USD. The Group's flagship company, Reliance Industries Limited is India's largest private sector company and a Fortune Global 100 company. RLS is a fully integrated life sciences industry player with in-house capabilities in research, pre-clinical and clinical development, process development, quality management, commercial-scale manufacturing, and marketing. For further information on Reliance Life Sciences please visit http://www.rellife.com/

**To be added to Medicure's e-mail list, pleasevisit:**http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor itsRegulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacyor accuracy of this release.

Forward Looking Information: Statementscontained in this press release that are not statements of historical fact, including, without limitation, statements containingthe words "believes", "may", "plans", "will", "estimates", "continues","anticipates", "intends", "expects" and similar expressions, may constitute "forward-lookinginformation" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking informationand forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-lookingstatements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perceptionof trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant andreasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factorsbeyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially differentfrom any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers arecautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's futureproduct revenues, the ability of AGGRASTAT^®^ to provide benefits to COVID-19 patients, expected futuregrowth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinicaltrials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependenceupon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological changein the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limitedto, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreignexchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvalsfor the Company's research and development projects; the availability of financing for the Company's commercial operations and/orresearch and development projects, or the availability of financing on reasonable terms; results of current and future clinicaltrials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing listof important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise reviseany forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additionaldiscussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filingswith the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "RiskFactors" section of its Form 20F for the year ended December 31, 2019.

View original content:http://www.prnewswire.com/news-releases/medicure-announces-an-agreement-with-reliance-life-sciences-for-the-marketing-rights-of-a-cardiovascular-biosimilar-301145432.html

SOURCE Medicure Inc.

View original content: http://www.newswire.ca/en/releases/archive/October2020/05/c2917.html

%CIK: 0001133519

For further information: James Kinley, Chief Financial Officer, Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com

CO: Medicure Inc.

CNW 08:30e 05-OCT-20